Eric P. Chow

Eric P. Chow

PhD, MScMed (Clinical Epidemiology), MBiostat, MPH, MApplSc (Bioinformatics), BSc

Infectious Disease Specialist

11 years of post-PhD experience

Male📍 Carlton

About of Eric P. Chow

Eric P. Chow is an Infectious Disease Specialist based in Carlton, Tasmania, working out of 580 Swanston Street, Carlton, TAS 3053.


Infectious diseases can be tricky. Symptoms can overlap, and the right treatment depends a lot on what’s causing the infection and how far it has spread. Eric helps people when infections affect the genitals, skin, gut, lungs, or the nervous system. He also looks after cases where there’s ongoing concern about sexually transmissible infections.


Many of the conditions he supports include common STIs such as gonorrhoea, chlamydia, syphilis, and trichomoniasis, along with genital herpes and genital warts. He also treats people with HIV/AIDS, human papillomavirus (HPV) related problems, and issues like cervicitis, urethritis, proctitis, pelvic inflammatory disease, and anal cancer. At times, patients come in with questions after exposure, repeated symptoms, or test results that don’t match what they’re feeling.


Beyond STIs, his work also covers infections that show up in other parts of the body. This can include hepatitis (such as hepatitis A), pneumonia, diarrhoea and viral gastroenteritis, and some viral outbreaks like COVID-19 and monkeypox. He also deals with conditions where infections can be more serious, especially when people have other health issues or need careful follow-up.


Over time, Eric has built experience through 11 years of post-PhD work. That background helps in day-to-day decision making, including thinking through test options, treatment choices, and what to monitor next.


His education includes a PhD in Epidemiology and Infectious Diseases from the University of New South Wales (2014). He also has an MScMed in Clinical Epidemiology from the University of Sydney (2022), plus training in biostatistics, public health, and bioinformatics. Degrees include MBiostat from the University of Melbourne (2017), an MPH in Public Health and Epidemiology from UNSW (2012), MApplSc (Bioinformatics) from the University of Sydney (2009), and a BSc in Biomedical Science from the University of Technology Sydney (2007).


Eric works with research and clinical knowledge gained from published work, and he may be involved in clinical trials through partner teams when appropriate for a patient’s situation. When a specific trial option is relevant, he focuses on clear, plain-language advice about what it could mean for care.

Education

  • PhD-Epidemiology / Infectious Diseases; University of New South Wales; 2014
  • MScMed (Clinical Epidemiology) -Clinical Epidemiology; University of Sydney; 2022
  • MBiostat - Biostatistics; University of Melbourne; 2017
  • MPH - Public Health / Epidemiology; UNSW; 2012
  • MApplSc (Bioinformatics); University of Sydney; 2009
  • BSc - Biomedical Science; University of Technology Sydney; 2007

Services & Conditions Treated

GonorrheaSyphilisCervicitisChlamydiaGenital WartsHIV/AIDSHuman Papillomavirus InfectionUrethritisWartsAnal CancerChancroidGenital HerpesLymphogranuloma VenereumPelvic Inflammatory DiseaseProctitisSevere Acute Respiratory Syndrome (SARS)TrichomoniasisAminoaciduriaBalanitisCervical CancerColorectal CancerCOVID-19DiarrheaFanconi Bickel SyndromeFanconi SyndromeHepatitisHepatitis AMolluscum ContagiosumMonkeypoxNeurosyphilisOral HerpesPerichondritisPneumoniaShigellosisTenesmusViral GastroenteritisYaws

Publications

5 total
Male-Partner Treatment to Prevent Recurrence of Bacterial Vaginosis.

The New England journal of medicine • March 05, 2025

Lenka Vodstrcil, Erica Plummer, Christopher Fairley, Jane Hocking, Matthew Law, Kathy Petoumenos, Deborah Bateson, Gerald Murray, Basil Donovan, Eric P Chow, Marcus Chen, John Kaldor, Catriona Bradshaw

Background: Bacterial vaginosis affects one third of reproductive-aged women, and recurrence is common. Evidence of sexual exchange of bacterial vaginosis-associated organisms between partners suggests that male-partner treatment may increase the likelihood of cure. Methods: This open-label, randomized, controlled trial involved couples in which a woman had bacterial vaginosis and was in a monogamous relationship with a male partner. In the partner-treatment group, the woman received first-line recommended antimicrobial agents and the male partner received oral and topical antimicrobial treatment (metronidazole 400-mg tablets and 2% clindamycin cream applied to penile skin, both twice daily for 7 days). In the control group, the woman received first-line treatment and the male partner received no treatment (standard care). The primary outcome was recurrence of bacterial vaginosis within 12 weeks. Results: A total of 81 couples were assigned to the partner-treatment group, and 83 couples were assigned to the control group. The trial was stopped by the data and safety monitoring board after 150 couples had completed the 12-week follow-up period because treatment of the woman only was inferior to treatment of both the woman and her male partner. In the modified intention-to-treat population, recurrence occurred in 24 of 69 women (35%) in the partner-treatment group (recurrence rate, 1.6 per person-year; 95% confidence interval [CI], 1.1 to 2.4) and in 43 of 68 women (63%) in the control group (recurrence rate, 4.2 per person-year; 95% CI, 3.2 to 5.7), which corresponded to an absolute risk difference of -2.6 recurrences per person-year (95% CI, -4.0 to -1.2; P<0.001). Adverse events in treated men included nausea, headache, and metallic taste. Conclusions: The addition of combined oral and topical antimicrobial therapy for male partners to treatment of women for bacterial vaginosis resulted in a lower rate of recurrence of bacterial vaginosis within 12 weeks than standard care. (Funded by the National Health and Medical Research Council of Australia; StepUp Australian New Zealand Clinical Trials Registry number, ACTRN12619000196145.).

Preferences of men who have sex with men towards the distribution of HIV self-test kits through social networks: A discrete choice experiment.

Journal Of Acquired Immune Deficiency Syndromes (1999) • May 30, 2025

Ying Zhang, Eric Chow, Tiffany Phillips, Christopher Fairley, Jason Ong

Objective: Social network distribution of HIV self-test (HIVST) kits uses social networks to increase HIV testing among marginalized populations, such as men who have sex with men (MSM). Using a discrete choice experiment (DCE), we identified factors influencing influence MSM's willingness and decision-making in HIVST kit distribution. Methods: An online DCE survey was conducted among MSM in Australia (December 2023-May 2024) via online/offline advertisements. Methods: Participants completed seven choice sets, each containing two hypothetical scenarios for HIVST kits distribution described by attributes such as cost, location, training, support system, and self-reporting methods. Mixed logit models and latent class analysis explored preference heterogeneity across language (English vs. non-English first language) and nativity (Australian-born vs. overseas-born) groups. Results: There were 251 participants, including 140 overseas-born MSM, with a mean age of 36.5 (SD=11.9). Participants who did not speak English as their first language (29/251,12%) showed a lower preference for paid HIVST kits ($30 or $60 for three kits) and online video chats with sexual health professionals as pre-test support. Overseas-born participants preferred not to attend 30-minute or one-hour training sessions on distributing HIVST kits. They did not like accessing HIVST kits from hospitals. Class 1 ('Cost-conscious and minimal support seekers';61.7%) were willing to pay up to $30 for three kits, while Class 2 ('Subsidy-dependent and structured support seekers';38.3%) disliked costs and self-reporting results by phone. Conclusions: Increasing participation in social network distribution of HIVST kits will require free or subsidized kits. Tailored support systems should prioritise overseas-born MSM with limited English proficiency.

Evaluation of artificial intelligence (AI) chatbots for providing sexual health information: a consensus study using real-world clinical queries.

BMC Public Health • March 15, 2025

Phyu Latt, Ei Aung, Kay Htaik, Nyi Soe, David Lee, Alicia King, Ria Fortune, Jason Ong, Eric P Chow, Catriona Bradshaw, Rashidur Rahman, Matthew Deneen, Sheranne Dobinson, Claire Randall, Lei Zhang, Christopher Fairley

Background: Artificial Intelligence (AI) chatbots could potentially provide information on sensitive topics, including sexual health, to the public. However, their performance compared to nurses and across different AI chatbots, particularly in the field of sexual health, remains understudied. This study evaluated the performance of three AI chatbots - two prompt-tuned (Alice and Azure) and one standard chatbot (ChatGPT by OpenAI) - in providing sexual health information on questions that experienced sexual health nurses could correctly answer. Methods: We analysed 195 anonymised sexual health questions received by the Melbourne Sexual Health Centre phone line. A panel of experts in a blinded order using a consensus-based approach evaluated responses to these questions from nurses and the three AI chatbots. Performance was assessed based on overall correctness and five specific measures: guidance, accuracy, safety, ease of access, and provision of necessary information. We conducted subgroup analyses for clinic-specific (e.g., opening hours) and general sexual health questions and a sensitivity analysis excluding questions that Azure could not answer. Results: Alice demonstrated the highest overall correctness (85.2%; 95% confidence interval (CI), 82.1-88.0%), followed by Azure (69.3%; 95% CI, 65.3-73.0%) and ChatGPT (64.8%; 95% CI, 60.7-68.7%). Prompt-tuned chatbots outperformed the base ChatGPT across all measures. Among all outcome measures, all chatbots performed best on safety, with Azure achieving the highest safety score (97.9%; 95% CI, 96.4-98.9%), indicating the lowest risk of providing potentially harmful advice. In subgroup analysis, all chatbots performed better on general sexual health questions compared to clinic-specific queries. Sensitivity analysis showed a narrower performance gap between Alice and Azure when excluding questions Azure could not answer. Conclusions: Prompt-tuned AI chatbots demonstrated superior performance in providing sexual health information compared to base ChatGPT, with high safety scores particularly noteworthy. However, all AI chatbots showed susceptibility to generating incorrect information. These findings suggest the potential for AI chatbots as adjuncts to human healthcare providers for providing sexual health information while highlighting the need for continued refinement and human oversight. Future research should focus on larger-scale evaluations and real-world implementations.

User Input in the Development of Digital Sexual Health Tools: A Scoping Review and Guidance for Tool Developers.

Health Expectations : An International Journal Of Public Participation In Health Care And Health Policy • March 12, 2025

Alicia King, Ethan Cardwell, Eric Chow, Paul Flowers, Mark Gilbert, Kath Albury

Studies reporting the use of digital tools to promote the prevention and treatment of sexually transmitted and blood borne infections (STBBIs) have proliferated in recent years. Previous reviews highlight variability in the input sought from users in tool development, and its contribution to impact. Objective: This scoping review sought to describe approaches to seeking and utilising user input, with the goal of providing guidance for developers. Methods: Searches were conducted in MEDLINE, PsycInfo, and the Social Science Citation Index and results screened by two reviewers. The reference lists of included studies and review papers were also checked. Methods: Peer reviewed qualitative and mixed methods studies seeking user input on digital tools promoting the prevention and treatment of STBBIs, from prototyping onwards, published from after 2014 in English, were included. Methods: Reported methods and findings were charted in Excel and synthesised using content analysis to provide an overview of methods and domains of user input and utilisation of this input. Results: A total of 1838 unique titles and abstracts and the full text of 50 publications were screened. Data was charted from 37 eligible studies reporting findings from 34 projects developing digital health tools, including smartphone/tablet applications, websites/web-based applications, chatbots, interactive automated SMS, and purpose-built tools within dating and social media applications. Studies reported on tools developed for use by diverse target populations. The most common domain of input reported was usability (n = 31), while others-namely, satisfaction (n = 27), acceptability (n = 25), formative (n = 24), impact (n = 22), accessibility (n = 17), and engagement (n = 11)-were reported less consistently. User views were sought using qualitative methods such as interviews, focus groups and open-ended survey questions, more often in combination with quantitative measures such as participant-rated measures and engagement analytics. User suggestions for changes were reported in relation to three in four projects studied but incorporation of changes in less than half of projects. Conclusions: This review demonstrates considerable homogeneity in reported user input in the development of digital health tools. Input from users as co-designers may improve the impact of tools on their intended outcomes. This literature review brought together a group of researchers who have sought user input in the development of digital sexual health tools, but, due to resource limitations, did not involve potential users themselves, who are of diverse and disparate groups.

Factors associated with primary care providers' recommendation of HPV vaccination for adolescent males in China: A mixed-methods study.

Vaccine • March 06, 2025

Meiling Li, Weiping Cai, Anjali Chandrasekhar, Hongyan Hu, Eric P Chow, Dan Wu

Background: The Chinese government has not yet included male population for HPV vaccination but there are increasingly more discussions about including them. Primary care providers' (PCPs) recommendation is an important driver for increasing vaccine uptake but understanding of PCPs' recommendation of HPV vaccine for adolescent males in China is limited. This study examined multidimensional factors associated with PCPs' recommendation of HPV vaccine for male adolescents, aiming to inform future HPV vaccination programs targeting adolescent males in China. Methods: A sequential explanatory mixed-methods was used. In the quantitative phase, we conducted an online survey with PCPs in Eastern China. Multivariable logistic regression analysis identified individual, interpersonal, community, organizational, and policy factors associated with their recommendation of HPV vaccines for adolescent males. Specialty, job title, and income were adjusted as potential confounding factors. The qualitative phase involved thematic analysis to explore these findings further. Results: Among the 605 PCPs recruited, only 16.4 % recommended HPV vaccines to adolescent males in the past 12 months. Multivariable logistic regression analysis showed that institutional support for HPV vaccination policies for adolescent males (AOR = 3.05, 95 % CI: 1.65-5.64), frequent institutional vaccine promotion activities (AOR = 1.82, 95 % CI: 1.12-2.96), and institutional incentives for vaccine promotion (AOR = 2.12, 95 % CI: 1.18-3.83) were associated with their recommendation behaviors. Additionally, those who perceived a community norm that HPV vaccines are only for females were less likely to recommend HPV vaccines to adolescent males (AOR = 0.54, 95 % CI: 0.33-0.87). Qualitative research further explained these findings, highlighting the role of organizational factors in PCPs' recommendation of HPV vaccination for adolescent males. Conclusions: A low proportion of PCPs recently recommended HPV vaccines to adolescent males. Organizational-level factors were found to be significantly associated with their recommendation behaviors, and these may help inform future vaccination programs targeting adolescent males.

Clinical Trials

1 total

Impact of the Daily Doxycycline Pre-exposure Prophylaxis (PrEP) on the Incidence of Syphilis, Gonorrhoea and Chlamydia

Active_not_recruiting

1. This study is a non-randomized observational cohort trial using before and after comparison to evaluate intervention 2. It would mimic the conditions that would occur outside a clinical trial. 2. After consent and enrolment, all procedures will be guided by the Australian STI Management Guidelines. 3. All enrolling participants will be offered daily doxycycline 100mg 4. All participants will be invited to complete a survey in every 3 months time for 12 months dated from participation. 5. All follow-up information will be collected through electronic data capture to allow accurate and timely analyses. 6. Data collection will be from (i) medical records (ii) online self-completed questionnaire

Participants: 100

Frequently Asked Questions

What services does Dr Eric P. Chow offer?
Dr Chow provides care for a range of infectious diseases and related conditions, including testing and management for gonorrhea, syphilis, chlamydia, genital warts, HIV/AIDS, hepatitis, COVID-19, and other infections listed in his services.
Which conditions or illnesses does Dr Chow commonly treat?
Common concerns include sexually transmitted infections such as gonorrhea, chlamydia, syphilis, genital herpes, and HPV; respiratory infections like pneumonia and COVID-19; hepatitis; and other infectious diseases as listed in his service range.
Where is Dr Chow's clinic located?
The clinic is at 580 Swanston Street, Carlton, TAS 3053, Australia.
How can I book an appointment with Dr Chow?
Appointments can be made by contacting the clinic directly at their Carlton location. Availability may vary, so it’s best to check current openings when you call.
What is Dr Chow’s background?
Dr Chow has a PhD and extensive training in clinical epidemiology, biostatistics, and public health, with over 11 years of post‑PhD experience as an infectious disease specialist.
What kinds of tests or treatments might be involved?
Tests and treatments depend on your condition. Common infectious disease care may involve diagnostics, counselling, and treatment plans for infections such as hepatitis, HIV, sexually transmitted infections, and other listed conditions.

Contact Information

580 Swanston Street, Carlton, TAS 3053, Australia

Is this your profile?

Claim this profile →

Memberships

  • IPVS (International Papillomavirus Society)
  • Sexual Health Society of Victoria
  • Victorian Government STI Advisory Committee